RecruitingPhase 4NCT05114096

Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery: To Keep Babies and Children Safe

Sponsor

McMaster University

Enrollment

3,254 participants

Start Date

Jul 20, 2023

Study Type

INTERVENTIONAL

Conditions

Pregnancy Complications Premature Birth Obstetric Labor, Premature Preterm Birth Complication of Prematurity

Summary

Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome. The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity. The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This trial tests whether one dose of a steroid medicine (rather than the standard two doses) is just as effective at helping premature babies' lungs develop before birth. You may be eligible if... - You are pregnant, aged 18-55, at risk of giving birth early (between 22 and 34 weeks) - You are pregnant with one baby or twins - You have received only a single dose of Celestone (betamethasone) within the last 24 hours You may NOT be eligible if... - You have a medical reason you cannot receive corticosteroids - You have been taking steroids during this pregnancy for another condition - You have previously participated in this trial - Your baby has a known severe condition or chromosomal abnormality - One or more of your babies has died after 14 weeks of pregnancy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCelestone + placebo

After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.

DRUGCelestone + Celestone

After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.

Locations(25)

University of Calgary, Cumming School of Medicine

Calgary, Alberta, Canada

Alberta Health Services; University of Alberta

Edmonton, Alberta, Canada

Royal Columbian Hospital

New Westminster, British Columbia, Canada

Fraser Health, University of British Columbia; Jim Pattison Outpatient Care and Surgery Centre

Surrey, British Columbia, Canada

University of British Columbia; BC Women's Hospital

Vancouver, British Columbia, Canada

Victoria General Hospital

Victoria, British Columbia, Canada

University of Manitoba, Health Sciences Centre

Winnipeg, Manitoba, Canada

University of Manitoba; St. Boniface General Hospital

Winnipeg, Manitoba, Canada

Dr. Everett Chalmers Regional Hospital

Fredericton, New Brunswick, Canada

The Moncton Hospital, Horizon Health Network

Moncton, New Brunswick, Canada

Memorial University, Eastern Health

St. John's, Newfoundland and Labrador, Canada

Dalhousie University; Izaak Walton Killam Health

Halifax, Nova Scotia, Canada

McMaster University

Hamilton, Ontario, Canada

Queen's University, Kingston General Hospital Health Sciences Centre

Kingston, Ontario, Canada

Western University; London Health Sciences Centre, Victoria Hospital

London, Ontario, Canada

University of Ottawa; The Ottawa Hospital

Ottawa, Ontario, Canada

Mount Sinai Hospital

Toronto, Ontario, Canada

Sunnybrook Health Sciences Center

Toronto, Ontario, Canada

Hopital Maisonneuve Rosemont, CIUSSS de l'est de l'Ile de Montréal

Montreal, Quebec, Canada

McGill University, McGill University Health Center, Royal Victoria Hospital

Montreal, Quebec, Canada

Sir Mortimer B. Davis Jewish General Hospital; McGill University

Montreal, Quebec, Canada

The Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal

Montreal, Quebec, Canada

Université Laval, Centre de recherche du CHU de Québec

Québec, Quebec, Canada

(CIUSSS de l'Estrie-CHUS); Université de Sherbrooke

Sherbrooke, Quebec, Canada

University of Saskatchewan, Regina General Hospital

Saskatoon, Saskatchewan, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05114096

Related Trials

Stress Phenotypes and Preterm Birth

NCT052296661 location

U-CaVIT Versus Standard of Care for Prevention of Atonic Postpartum Hemorrhage After Cesarean Section in High-risk Women.

NCT070196231 location

Glycemic Markers for Predicting Gestational Diabetes in Pregnant Women With Previous Bariatric Surgery

NCT075174061 location

Health-Related Quality-of-Life and Household Financial and Wellbeing Impacts of Prematurity and Necrotising Enterocolitis (NEC).

NCT071923937 locations

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

NCT031520583 locations